ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

APS Aptose Biosciences Inc

1.68
-0.01 (-0.59%)
Last Updated: 15:03:03
Delayed by 15 minutes
Share Name Share Symbol Market Type
Aptose Biosciences Inc TSX:APS Toronto Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.01 -0.59% 1.68 1.68 1.71 1.71 1.68 1.71 577 15:03:03

Aptose Biosciences to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

05/09/2017 1:30pm

GlobeNewswire Inc.


Aptose Biosciences (TSX:APS)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Aptose Biosciences Charts.

Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainright & Co., LLC., on Monday, September 11, 2017 at 9:35 a.m. ET at the Lotte New York Palace Hotel in New York, NY.

Dr. Rice will provide a corporate overview of the Company’s recent activities and strategic direction.

Time:    9:35 a.m. ET
Date:    Monday, September 11, 2017
Location:    Lotte New York Palace Hotel, New York, NY
      

A live webcast of the Aptose presentation will be accessible by visiting:

http://wsw.com/webcast/rrshq27/apto

The webcast will be archived shortly after the live event and will be available for 90 days through the Aptose website at www.aptose.com

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.

For further information, please contact:

Aptose Biosciences
Greg Chow, CFO
647-479-9828
gchow@aptose.com

SMP Communications
Susan Pietropaolo
201-923-2049
susan@smpcommunications.com

1 Year Aptose Biosciences Chart

1 Year Aptose Biosciences Chart

1 Month Aptose Biosciences Chart

1 Month Aptose Biosciences Chart

Your Recent History

Delayed Upgrade Clock